JX Partners
VC Fund
Seoul, South Korea
JX Partners is a venture capital firm.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries JX Partners invests in
Stages JX Partners invests in
Countries JX Partners invests in
Round sizes
Round size
- Series A
- $5.9M–$8.4M
- Series B
- $10M–$11M
- Series C
- $7.2M–$33M
Investment Focus
Industry
- Biotechnology 5 (45%)
- Health Care 3 (27%)
- Biopharma 2 (18%)
- 3D Technology 2 (18%)
- Manufacturing 2 (18%)
Stage
- Series A 3 (27%)
- Series C 3 (27%)
- Series B 2 (18%)
- Venture - Series Unknown 2 (18%)
- Seed 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nexusbe
|
Nexusbe is a manufacturer of atomic layer equipment technology intended to provide vacuum deposition equipment. | $7.2M / Series C / Jun 18, 2026 | |
Specs
|
Specs offer satellite data analysis services using advanced 3D hyperspectral technology and develop satellite-mounted observation equipment. Specs plans to commercialize hyperspectral technology for Earth observation, transforming 3D astronomical spectroscopy into high-precision satellite data collection and analysis, ensuring high-qualitysatellite data. | $2M / Seed / Jun 09, 2026 | |
Polaris3D
|
Polaris3d offers indoor autonomous navigating solution. | $10.9M / Series B / Jun 03, 2024 | |
Curocell
|
Curocell’s OVIS™ technology enhances immune cells to overcome immune suppression in tumor microenvironments. | $30.1M / Venture - Series Unknown / Jan 04, 2022 | |
BeyondBio
|
BeyondBio is a biotechnology firm that specializes in the research and development of synthetic pharmaceutical drugs. | $13.6M / Venture - Series Unknown / Aug 22, 2021 | |
Cell in Cells
|
Cell in Cells is a biotechnology and life sciences company. It is involved in cell therapy and regenerative medicine. The company developed Therapeutic Organoid Intelligence, a proprietary platform to harness cells' self-organizing potential to regenerate and restructure tissues without synthetic scaffolds. | $10.4M / Series B / Jul 26, 2021 | |
MEZOO
|
MEZOO is a medical device manufacturing company. | $8.1M / Series A / Jun 02, 2021 | |
Shaperon
|
Shaperon is a clinical-stage biotech company that develops inflammasome inhibitors. | $19.3M / Series C / Oct 20, 2020 | |
|
Curocell
|
Curocell’s OVIS™ technology enhances immune cells to overcome immune suppression in tumor microenvironments. | $37.1M / Series C / Aug 10, 2020 | |
Novelty Nobility
|
Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role.In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF)and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development. | $8.4M / Series A / Feb 04, 2020 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does JX Partners invest in?
JX Partners invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series C stage. Most of the 11 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is JX Partners's check size?
JX Partners typically joins rounds of $5.9M–$8.4M at Series A, $10M–$11M at Series B and $7.2M–$33M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds JX Partners participates in.
When did JX Partners last invest?
The most recent investment recorded for JX Partners closed in Jun 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
